Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-05-16

Clinical Trial Update: Adalimumab vs. Conventional Immunosuppression for Uveitis Trial [Phase 3]

View source ↗

Summary

Phase 3 trial comparing adalimumab to conventional immunosuppression for uveitis has completed. Results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ADALIMUMAB (ADALIMUMAB-AATY)

Snippet

Sponsor: JHSPH Center for Clinical Trials | Conditions: Uveitis | Phase 3 | Status: COMPLETED | Results posted: 2025-05-16